Early inflammatory response of knee ligaments to prolotherapy in a rat model

Journal of Orthopaedic Research

Volumn 26, Issue 6, 2008, Pages 816-823

  Jensen, Kristina T ^a,b   Rabago, David P ^c   Best, Thomas M ^d   Patterson, Jeffrey J ^c   Vanderby Jr , Ray ^a,b  

^a University of Wisconsin Madison   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Dextrose; Needlestick; P2G; Saline; Sodium morrhuate

Indexed keywords

COLLAGENASE; GLUCOSE; MORRHUATE SODIUM; PHENOL GLUCOSE GLYCERINE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLYCEROL; LEUKOSIALIN; PHENOL; SCLEROSING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNEE LIGAMENT; LEUKOCYTE; MACROPHAGE; NONHUMAN; PAIN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROLOTHERAPY; RAT; SOFT TISSUE INJURY; THERAPY; ANIMAL; ARTHRITIS; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; IMMUNOLOGY; METABOLISM; NEEDLESTICK INJURY; NEUTROPHIL; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIGENS, CD43; ARTHRITIS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GLUCOSE; GLYCEROL; MACROPHAGES; MEDIAL COLLATERAL LIGAMENT, KNEE; NEEDLESTICK INJURIES; NEUTROPHILS; PHENOL; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; SCLEROSING SOLUTIONS; SODIUM CHLORIDE; SODIUM MORRHUATE;

EID: 46449122012     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20600     Document Type: Article

References (60)

1. Woodwell DA, Cherry DK. 2004. National Ambulatory Medical Care Survey: 2002 summary. Adv Data 346:1-44.
2. McCaig LF, Nawar EN. 2006. National Hospital Ambulatory Medical Care Survey: 2004 Emergency Department Summary. Advance data from vital and health statistics; no. 372. Hyattsville, MD: National Center for Health Statistics.
3. Palesy PD. 1997. Tendon and ligament insertions - a possible source of musculoskeletal pain. Cranio 15:194-202.
4. Scavenius M, Bak K, Hansen S, et al. 1999. Isolated total ruptures of the anterior cruciate ligament - a clinical study with long-term follow-up of 7 years. Scand J Med Sci Sports 9:114-119.
5. Felson DT, Lawrence RC, Dieppe PA, et al. 2000. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 133:635-646.
6. Andriachi T, Sabiston P, De Haven K, et al. 1987. Injury and Repair of the Musculoskeletal Soft Tissues. In: Woo SY, Buckwalter JA, editors. Ligament: Injury and Repair. Park Ridge, IL: AAOS; pp 103-128.
7. Wilson JJ, Best TM. 2005. Common overuse tendon problems: A review and recommendations for treatment. Am Fam Physician 72:811-818.
8. Stovitz SD, Johnson RJ. 2003. NSAIDS and musculoskeletal treatment: What is the evidence? Physician Sports Med 31:35-52.
9. Assendelft WJ, Hay EM, Adshead R, et al. 1996. Corticosteroid injections for lateral epicondylitis: a systematic overview. Br J Gen Pract 46:209-216.
10. Bisset L, Beller E, Jull G, et al. 2006. Mobilisation with movement and exercise, corticosteroid injection, or wait and see for tennis elbow: randomised trial. BMJ 333:939.
11. Matthews JH. 1999. Nonsurgical treatment of pain in lumbar spine stenosis. Am Fam Physician 59:280, 283-284.
12. Schnirring L. 2000. Are Your Patients Asking About Prolotherapy? Physician Sports Med 28:15-17.
13. Rabago D, Best T, Beamsley M, et al. 2005. A systematic review of prolotherapy for chronic musculoskeletal pain. Clin J Sport Med 15:376-380.
14. Dorman TA. 1993. Prolotherapy: a survey. J Orthop Med 15:49-50.
15. Dagenais S, Ogunseitan O, Haldeman S, et al. 2006. Side effects and adverse events related to intraligamentous injection of sclerosing solutions (prolotherapy) for back and neck pain: A survey of practitioners. Arch Phys Med Rehabil 87:909-913.
16. Linetsky FS, Rafael M, Saberski L. 2002. Pain management with regenerative injection therapy (RIT). In: Weiner RS, editor. Pain Management. Boca Raton, FL: CRC Press; pp 381-402.
17. Dechow E, Davies RK, Carr AJ, et al. 1999. A randomized, double-blind, placebo-controlled trial of sclerosing injections in patients with chronic low back pain. Rheumatology 38:1255-1259.
18. Klein RG, Eek BC, DeLong WB, et al. 1993. A randomized double-blind trial of dextrose-glycerine-phenol injections for chronic, low back pain. J Spinal Disord 6:23-33.
19. Ongley MJ, Klein RG, Dorman TA, et al. 1987. A new approach to the treatment of chronic low back pain. Lancet 2:143-146.
20. Yelland MJ, Glasziou PP, Bogduk N, et al. 2004. Prolotherapy injections, saline injections, and exercises for chronic low-back pain: a randomized trial. Spine 29:9-16.
21. Reeves KD, Hassanein K. 2000. Randomized, prospective, placebo-controlled double-blind study of dextrose prolotherapy for osteoarthritic thumb and finger (DIP, PIP, and trapeziometacarpal) joints: evidence of clinical efficacy. J Altern Complement Med 6:311-320.
22. Reeves KD, Hassanein K. 2000. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. Altern Ther Health Med 6:68-74, 77-80.
23. Scarpone M, Rabago D, Zgierska A, et al. 2007. The efficacy of prolotherapy for lateral epicondylosis: a pilot study. Clin J Sport Med, in press.
24. Banks A. 1991. A rationale for prolotherapy. J Orthop Med 13:54-59.
25. Natarajan R, Gonzales N, Xu L, et al. 1992. Vascular smooth muscle cells exhibit increased growth in response to elevated glucose. Biochem Biophys Res Commun 187:552-560.
26. McGinn S, Poronnik P, King M, et al. 2003. High glucose and endothelial cell growth: novel effects independent of autocrine TGF-beta 1 and hyperosmolarity. Am J Physiol Cell Physiol 284:C1374-1386.
27. Kondo S, Beissert S, Wang B, et al. 1996. Hyporesponsiveness in contact hypersensitivity and irritant contact dermatitis in CD4 gene targeted mouse. J Invest Dermatol 106:993-1000.
28. Pedersen G, Brynskov J, Saermark T. 2002. Phenol toxicity and conjugation in human colonic epithelial cells. Scand J Gastroenterol 37:74-79.
29. Gunduz S, Kalyon TA, Dursun H, et al. 1992. Peripheral nerve block with phenol to treat spasticity in spinal cord injured patients. Paraplegia 30:808-811.
30. Westerlund T, Vuorinen V, Kirvela O, et al. 1999. The endoneurial response to neurolytic agents is highly dependent on the mode of application. Reg Anesth Pain Med 24:294-302.
31. Dagenais S, Mayer J, Haldeman S, et al. 2006. Dose-Escalation, Placebo-Controlled Acute Toxicity Evaluation of a Drug Commonly Used in Prolotherapy Following Spinal Injection in Rats. In: NASS 21st Annual Meeting. Spine J, p 76S.
32. Dagenais S, Ogunseitan O, Haldeman S, et al. 2006. Acute Toxicity Pilot Evaluation of Proliferol in Rats and Swine. Int J Toxicol 25:171-181.
33. de Lorimier AA. 1995. Sclerotherapy for venous malformations. J Pediatr Surg 30:188-193; discussion 194.
34. Stroncek DF, Hutton SW, Silvis SE, et al. 1985. Sodium morrhuate stimulates granulocytes and damages erythrocytes and endothelial cells: probable mechanism of an adverse reaction during sclerotherapy. J Lab Clin Med 106:498-504.
35. Aneja A, Karas SG, Weinhold PS, et al. 2005. Suture plication, thermal shrinkage, and sclerosing agents: effects on rat patellar tendon length and biomechanical strength. Am J Sports Med 33:1729-1734.
36. Liu YK, Tipton CM, Matthes RD, et al. 1983. An in situ study of the influence of a sclerosing solution in rabbit medial collateral ligaments and its junction strength. Connect Tissue Res 11:95-102.
37. Maynard JA, Pedrini VA, Pedrini-Mille A, et al. 1985. Morphological and biochemical effects of sodium morrhuate on tendons. J Orthop Res 3:236-248.
38. Harrison MEG. 1995. The Biomechanical Effects of Prolotherapy on Traumatized Achilles Tendons of Male Rats. In: Department of Physical Education. Provo, Utah: Brigham Young University.
39. Lewit K. 1979. The needle effect in the relief of myofascial pain. Pain 6:83-90.
40. Tidball JG, Berchenko E, Frenette J. 1999. Macrophage invasion does not contribute to muscle membrane injury during inflammation. J Leukoc Biol 65:492-498.
41. Frenette J, Cai B, Tidball JG. 2000. Complement activation promotes muscle inflammation during modified muscle use. Am J Pathol 156:2103-2110.
42. Wetzel BJ, Nindl G, Swez JA, et al. 2002. Quantitative characterization of rat tendinitis to evaluate the efficacy of therapeutic interventions. Biomed Sci Instrum 38:157-162.
43. Sun D, Tani M, Newman TA, et al. 2000. Role of chemokines, neuronal projections, and the blood-brain barrier in the enhancement of cerebral EAE following focal brain damage. J Neuropathol Exp Neurol 59:1031-1043.
44. Dijkstra CD, Dopp EA, Joling P, et al. 1985. The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2 and ED3. Immunology 54:589-599.
45. Shimokado K, Raines EW, Madtes DK, et al. 1985. A significant part of macrophage-derived growth factor consists of at least two forms of PDGF. Cell 43:277-286.
46. Paulsson Y, Hammacher A, Heldin CH, et al. 1987. Possible positive autocrine feedback in the prereplicative phase of human fibroblasts. Nature 328:715-717.
47. Heldin CH, Westermark B. 1999. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79:1283-1316.
48. Miller KM, Anderson JM. 1989. In vitro stimulation of fibroblast activity by factors generated from human monocytes activated by biomedical polymers. J Biomed Mat Res 23:911-930.
49. Head CC, Farrow MJ, Sheridan JF, et al. 2006. Androstenediol reduces the anti-inflammatory effects of restraint stress during wound healing. Brain Behav Immun 20:590-596.
50. Zhou FH, Foster BK, Sander G, et al. 2004. Expression of proinfiammatory cytokines and growth factors at the injured growth plate cartilage in young rats. Bone 35:1307-1315.
51. Ostendorf T, van Roeyen CR, Peterson JD, et al. 2003. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J Am Soc Nephrol 14:2237-2247.
52. Andrieu-Soler C, Berdugo M, Doat M, et al. 2005. Down-regulation of IRS-1 expression causes inhibition of corneal angiogenesis. Invest Ophthalmol Vis Sci 46:4072-4078.
53. Testa V, Capasso G, Benazzo F, et al. 2002. Management of Achilles tendinopathy by ultrasound-guided percutaneous tenotomy. Med Sci Sports Exerc 34:573-580.
54. Haake M, Müller H, Schade-Brittinger C, et al. 2007. German Acupuncture Trials (GERAC) for chronic low back pain. Randomized, multicenter, blinded, parallel-group trial with 3 groups. Arch Intern Med 167:1892-1898.
55. Connell DA, Ali KE, Ahmad M, et al. 2006. Ultrasound-guided autologous blood injection for tennis elbow. Skeletal Radiol 35:371-377.
56. Edwards SG, Calandruccio JH. 2003. Autologous blood injections for refractory lateral epicondylitis. J Hand Surg [Am] 28:272-278.
57. Kawamura S, Ying L, Kim HJ, et al. 2005. Macrophages accumulate in the early phase of tendon-bone healing. J Orthop Res 23:1425-1432.
58. Lavagnino M, Arnoczky SP, Frank K, et al. 2005. Collagen fibril diameter distribution does not reflect changes in the mechanical properties of in vitro stress-deprived tendons. J Biomech 38:69-75.
59. Provenzano PP, Alejandro-Osorio AL, Valhmu WB, et al. 2005. Intrinsic fibroblast-mediated remodeling of damaged collagenous matrices in vivo. Matrix Biol 23:543-555.
60. Hannawa KK, Eliason JL, Woodrum DT, et al. 2005. L-selectin-mediated neutrophil recruitment in experimental rodent aneurysm formation. Circulation 112:241-247.